Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020
Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020
SUMMARY
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.
The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Women's Health which include indications Idiopathic Pulmonary Fibrosis, Atherosclerosis, Cardiomyopathy, Coronavirus Disease 2019 (COVID-19), Diabetic Neuropathic Pain, Fibrosis, Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Polycystic Ovarian Syndrome, Postherpetic Neuralgia, Skin Inflammation, Systemic Sclerosis (Scleroderma) and Wounds.
Furthermore, this report also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.
The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Women's Health which include indications Idiopathic Pulmonary Fibrosis, Atherosclerosis, Cardiomyopathy, Coronavirus Disease 2019 (COVID-19), Diabetic Neuropathic Pain, Fibrosis, Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Polycystic Ovarian Syndrome, Postherpetic Neuralgia, Skin Inflammation, Systemic Sclerosis (Scleroderma) and Wounds.
Furthermore, this report also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
- The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
CJ HealthCare Corp
KinDex Pharmaceuticals Inc
MorphoSys AG
Novartis AG
Novopyxis Inc
Vicore Pharma AB
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
(amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-6A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olodanrigan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize AGTR2 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones
Featured News & Press Releases
Mar 31, 2020: Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection
Mar 30, 2020: Vicore submits clinical trial application for phase II trial with C21 in IPF
Dec 18, 2019: Update on progress for drug development program VP02 (IMiD)
Dec 18, 2019: Update on progress for drug development program VP01 (C21)
Oct 01, 2019: Update on progress in clinical lead program VP01 (C21)
Sep 06, 2019: Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study
Apr 23, 2019: Vicore Pharma announces systemic sclerosis as the second indication for VP01
Sep 10, 2018: Vicore Pharma expands VP01 (C21) clinical program to enable functional read out
Jul 05, 2018: Non-opioid drug relieves pain in mice, targets immune cells
Apr 18, 2018: Vicore Pharma receives approval to start Phase IIa study in IPF
Mar 21, 2018: Frontiers in Physiology publish data with C21 on pulmonary fibrosis
Jan 26, 2018: Highlights from new publications on C21 and the AT2 receptor
Dec 22, 2017: Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis
Oct 09, 2017: Clinical Potential of C21 Highlighted in Review Publications
Oct 02, 2017: Phase I extension study demonstrates beneficial effects on lipid metabolism with C21
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
CJ HealthCare Corp
KinDex Pharmaceuticals Inc
MorphoSys AG
Novartis AG
Novopyxis Inc
Vicore Pharma AB
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
(amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-6A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olodanrigan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize AGTR2 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones
Featured News & Press Releases
Mar 31, 2020: Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection
Mar 30, 2020: Vicore submits clinical trial application for phase II trial with C21 in IPF
Dec 18, 2019: Update on progress for drug development program VP02 (IMiD)
Dec 18, 2019: Update on progress for drug development program VP01 (C21)
Oct 01, 2019: Update on progress in clinical lead program VP01 (C21)
Sep 06, 2019: Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study
Apr 23, 2019: Vicore Pharma announces systemic sclerosis as the second indication for VP01
Sep 10, 2018: Vicore Pharma expands VP01 (C21) clinical program to enable functional read out
Jul 05, 2018: Non-opioid drug relieves pain in mice, targets immune cells
Apr 18, 2018: Vicore Pharma receives approval to start Phase IIa study in IPF
Mar 21, 2018: Frontiers in Physiology publish data with C21 on pulmonary fibrosis
Jan 26, 2018: Highlights from new publications on C21 and the AT2 receptor
Dec 22, 2017: Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis
Oct 09, 2017: Clinical Potential of C21 Highlighted in Review Publications
Oct 02, 2017: Phase I extension study demonstrates beneficial effects on lipid metabolism with C21
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by CJ HealthCare Corp, H1 2020
Pipeline by KinDex Pharmaceuticals Inc, H1 2020
Pipeline by MorphoSys AG, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Novopyxis Inc, H1 2020
Pipeline by Vicore Pharma AB, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by CJ HealthCare Corp, H1 2020
Pipeline by KinDex Pharmaceuticals Inc, H1 2020
Pipeline by MorphoSys AG, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Novopyxis Inc, H1 2020
Pipeline by Vicore Pharma AB, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
CJ HealthCare Corp
KinDex Pharmaceuticals Inc
MorphoSys AG
Novartis AG
Novopyxis Inc
Vicore Pharma AB
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
CJ HealthCare Corp
KinDex Pharmaceuticals Inc
MorphoSys AG
Novartis AG
Novopyxis Inc
Vicore Pharma AB
